Logo

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Share this
Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Shots:

  • The first patient has been dosed in the P-II trial assessing IBI302 in patients with active subfoveal or parafoveal choroidal neovascularization secondary to nAMD. The primary objective is to evaluate the efficacy and safety of IBI302
  • The two P- I studies of IBI302 (single/multiple-dose escalation) showed improvement in visual acuity with a reduction in retinal thickness- leakage- and total area of neovascularization in terms of efficacy
  • Additionally- the ongoing P-II study of the therapy will focus on improving visual acuity and retinal thickness and the effect on macular atrophy and fibrosis

  Ref: PRNewswire | Image: Innovent

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions